MONTVALE, NJ –November 7, 2023 —EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) today provides an update on its clinical program for its lead drug candidate EOM613. EOM613 is a peptide-nucleic acid-based broad spectrum immune regulating agent that acts on both key pro-inflammatory and anti-inflammatory cytokines with potential therapeutic utility in treating a variety of acute and chronic inflammatory conditions.
This agent has been previously shown to regulate cytokine expression in a variety of immune cells in cell culture, and more recently in a Phase 1/2a human clinical trial in patients hospitalized COVID-19 with cytokine-driven respiratory inflammation. Recently reported results of this trial, named RESCUE, indicated marked beneficial reductions of the soluble interleukin-2 receptor protein (sIL-2R) cytokine levels in treated patients, with a concomitant mitigation of the release of the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-alpha).
To rescue, repair, and restore health in patients suffering
from debilitating and sometimes deadly diseases
Support each other and humankind
EOM Pharmaceuticals’ goal is to rescue, repair, and restore health. We are focused on developing novel drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases.
Rethinking the Role of Immunomodulators
Watch how EOM Pharmaceuticals is rethinking the role of immunomodulators with its novel, dynamically dual-acting, broad-spectrum lead asset, EOM613, which can produce anti- and pro-inflammatory effects and could mitigate a hyperimmune reaction or “cytokine storm.”